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Abstract
The emergence of antibiotic resistance in potential bacterial pathogens 
is considered as an important consequence of antibiotic misuse and 
overuse in humans and animals. In addition, lacks of adequate knowl-
edge about proper using of antimicrobial drugs as well as infection-
control practice in hospital and medical care settings have led to the 
continuing development of extensive antimicrobial resistance prob-
lems worldwide. Certain multidrug-resistant commensal and potential 
pathogens are now widely spread in community and hospital patients. 
Examples are meticillin-resistant Staphylococcus aureus (MRSA), vanco-
mycin-resistance enterococcci (VRE), extended-spectrum β-lactamase 
and carbapenemase-producing coliforms, floroquinolone-resistant 
and toxin-hyperproducing Clostridium difficile. During the last decade, 
Enterococcus faecalis and Enterococcus faecium were the most preva-
lent species cultured from human infections. Incidence of resistant 
to multiple antibiotics in these two species has become increasingly 
common in the hospitalized patients all over the world, particularly E. 
faecium  is reported to be responsible for most vancomycin-resistant 
enterococci (VRE) infections. 
This short review is focusing on the recent emergence of antimicrobial 
resistance among enterococci isolates from infants and the available 
option of their infection treatment.
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Introduction
Enterococci are common communsals of human 
and animal intestinal microflora. Enterococci are also 
among the frequent early colonizers in the intestine 
of breastfed infants [1]. E.faecalis and E. faecium are 
the most prevalent species cultured from human 
infections and are increasing to become associated 
with nosocomial infections [2-3]. The emergence of 
vancomycin- resistance enterococci (VRE) during re-
cent years has seriously affected the treatment and 
infection control of these organisms. VRE, particu-
larly E faecium strains, are frequently resistant to all 
antibiotics that are effective for the treatment of 
vancomycin-susceptible enterococci. This new de-
velopment leaves clinicians treating VRE infections 
with limited therapeutic options [4-5]. 
An increase in the prevalence of E.faecium has been 
recently observed to occur among neonatal patients 
in ICUs of many countries. This shift is likely to be 
explained in part by the rapid emergence of VRE 
[3-4]. 
Enterococci are intrinsically resistance to many an-
tibiotics, including the following agents: semisyn-
thetic penicillins such as oxacillin, cephalosporins of 
all classes, monobactams and polymyxins. Amino-
glycosides show insusceptibility at a low level, most 
probably due to a reduced uptake. In addition, ente-
rococci are relatively resistant to chemical disinfect-
ants such as chlorine, gluteraldehyde and alcohol 
[6-7]. 
Enterococci may develop increased resistance to 
penicillins through acquisition of β-lactamases or 
PBP/5 mutations [7 ]. High-level penicillin and am-
picillin resistance in E. faecium is mediated via point 
mutations in the house-keeping pbp5 gene lead-
ing to reduced penicillin binding to the expressed 
protein [8]. Almost exclusively strains of E. faecalis 
can express β- lactamase enzymes that confer high 
level resistance against all penicillins, except those 
combined to β-lactamase inhibitors (sulbactam or 
clavulanate). The enterococcal penicillinase gene is 
often found on a transferable plasmid [8] .
While intrinsic mechanisms result in low level ami-
noglycoside resistance, acquisition of mobile ge-
netic elements typically contributes to high-level 
aminoglycoside resistance in both E. faecium and 
E. faecalis [9].Only the two aminoglycosides; gen-
tamicin and streptomycin show a synergistic effect 
when given in combination with a cell-wall active 
agent like a penicillin or glycopeptides [9]. Certain 
aminoglycoside-modifying enzymes mediate high-
level gentamicin and streptomycin resistance in E. 
faecalis and E. faecium [9]. Glycopeptide antibiotics, 
vancomycin and teicoplanin, are used in the treat-
ment of serious enterococci infections in cases of 
resistance or allergy to β-lactams. Resistant strains 
which are responsible for colonization or infection 
have been isolated with an increasing frequency 
from patients in the presence or absence of glyco-
peptide therapy [10-11]. Vancomycin and teicoplanin 
inhibit cell wall synthesis through binding to the D-
alanyl-D-alanine (D-ala-D-ala) terminus of the pep-
tidoglycan precursors which prevents this precursor 
from participating further in the synthesis of cell 
wall [11]. According to the Clinical and Laboratory 
Standards Institute (CLSI), the following are the MIC 
interpretative criteria for vancomycin in enterococ-
ci: (i)susceptible ≤4 μg/ml, (ii)intermediate-8–16 μg/
ml,(iii)resistant ≥32 μg/ml [12].
Enterococci carry a wide variety of mobile genetic 
elements, and are considered to be a reservoir for 
the antibiotic resistance genes acquired by other 
gram-positive bacteria [13]. Both E.faecalis and E. 
faecium either isolated from human or dairy prod-
ucts at the same time showed fast similar resistance 
patterns against a wide variety of antibiotics, includ-
ing glycopeptide such as vancomycin and teicopla-
nin [14]. Widespread use of vancomycin and ex-
tended spectrum cephalosporins in hospitals is likely 
to have contributed to the emergence and dramatic 
increase of VRE over the past 20 years [15]. VRE may 
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be transmitted from patient to patient by the hands 
of healthcare workers and medical devices and of-
ten have virulence traits that enhance their ability to 
colonize rapidly hospitalized patients leading to the 
development of serious infections [14-16]. Different 
types of vancomycin-resistance genes have been re-
ported in enterococci. Glycopeptide-resistant geno-
types in enterococci include VanA (high-level resist-
ance), VanB and VanD with moderate to high-level 
resistance and VanC (C1, C2, C3) causing intrinsic 
low-level resistance [2]. 
In Europe and United States, the 3 most common 
vancomycin-resistance enterococci phenotypes de-
tected were VanA, VanB, and VanD. Enterococci VanA 
isolates exhibit high-level resistance to both vanco-
mycin and teicoplanin, while VanB isolates have vari-
able resistance to vancomycin and remain susceptible 
to teicoplanin. The VanC phenotype is mediated by 
the chromosomal  VANC1 and VANC2 genes, which 
are constitutively present in E. gallinarum  (VANC1) 
and  E. casseliflavus  (VANC2). These genes confer 
relatively low resistance levels to vancomycin and 
are not transferable. To date, the VanD, VanE, and 
VanG phenotypes have been described in only a 
few strains of enterococci [17]. 
Epidemiology of enterococci 
resistance in infants
A recent study in Pakistan reported by Yameen et 
al. [18], evaluated the incidence of nasal and rec-
tal colonization of vancomycin-sensitive and resist-
ant enterococci in patients of pediatrics ICU (PICU) 
.The nasal and rectal swab samples were collected 
from 110 patients admitted in PICUs in three ter-
tiary care hospitals of Rawalpindi Medical College, 
Pakistan. The identification of enterococci was done 
by biochemical tests and by PCR for ddl, vanA and 
vanB genes. Antibiotic susceptibility testing was 
performed by disc diffusion and MICs were deter-
mined for vancomycin, tetracycline, ciprofloxacin 
and oxacillin. Out of 220 nasal and rectal samples, 9 
vancomycin-resistant enterococci (VRE) and 76 van-
comycin-susceptible enterococci (VSE), consisting of 
40 E. faecalis and 45 E. faecium. Generally, E. fae-
cium isolates were more resistant than E. faecalis. 
MICs of vancomycin for nasal and rectal VRE were 
512 mg/L and 64 to 512 mg/L, respectively. 
A study from Mexico by Ochoa, et al. [19], has in-
vestigated distribution of multidrug-resistant Ente-
rococcus faecium isolates in a tertiary care center. 
Twelve clinical vancomycin-resistant Enterococcus 
faecium (VREF) isolates were obtained from pediat-
ric patients at the Hospital Infantil de México Fed-
erico Gómez (HIMFG). Among these VREF isolates, 
58.3% (7/12) were recovered from urine, while 
41.7% (5/12) were recovered from the bloodstream. 
The VREF isolates showed a 100% rate of resistance 
to ampicillin, amoxicillin-clavulanate, ciprofloxacin, 
clindamycin, chloramphenicol, streptomycin, gen-
tamicin, rifampicin, erythromycin and teicoplanin. In 
addition, 16.7% (2/12) of the isolates were resistant 
to linezolid, and 66.7% (8/12) were resistant to tet-
racycline and doxycycline. PCR analysis revealed the 
presence of the vanA gene in all 12 VREF isolates.
A study from Greece demonstrated high incidence 
of antibiotic resistance in enterococci isolated from 
neonates’ gut microbiota [20]. The study showed 
the prevalence of fecal enterococci in Greek healthy 
infants and their susceptibility to antimicrobial 
agents as well as the presence of genetic deter-
minants encoding for certain antibiotic resistance 
traits. A total of 263 fecal samples derived from 
97 infants were collected on day 4, 30, and 90 
after delivery. E. faecalis was the most frequently 
identified species (54.6%) followed by E. faecium, 
while E. casseliflavus,E. flavescens and E. gallinarum 
were also traced. The isolates were examined for 
their resistance to 12 antibiotics. Rifampicin resist-
ance was the highest observed (53.2%), followed 
by resistance to tetracycline (42.0%), erythromycin 
(35.7%), and vancomycin (11.2%). Multiresistant 
strains were highly prevalent. Only intrinsic vanco-
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mycin resistance (vanC1 and vanC2/C3 genes) was 
traced. The ermB gene was detected in 49 out of 
96 erythromycin-resistant isolates, while tet genes 
were detected in 51 out of 113 tetracycline-resistant 
strains, with tet(L) being the most frequently ob-
served. The study conclude that antibiotic-resistant 
enterococci are already established in the fecal mi-
crobiota of healthy neonates, from the first days of 
an infant’s life.
The study of Werner and his colleagues in Germany 
[4], has described an ongoing high prevalence of 
VanB type E. faecium in a neonatal ICU .During a 10 
months’ key period 71 E. faecium isolates including 
67 vanB-type isolates from 61 patients were col-
lected non-selectively. Vancomycin resistance was 
determined by different MIC methods (broth mi-
crodilution, VitekW 2) including two Etest protocols 
(McFarland 0.5/2.0. on Mueller-Hinton/Brain Heart 
Infusion agars). Performance of three chromogenic 
VRE agars to identify the vanB type outbreak VRE 
was evaluated. Majority of vanB isolates (n = 56, 
79%) belonged to a single ST192 outbreak strain 
type.Vancomycin MICs in cation-adjusted MH broth 
revealed a susceptible value of ≤4 mg/L for 31 (55%) 
of the 56 outbreak VRE isolates. Etest vancomycin 
on MH and BHI agars revealed only two vanB VRE 
isolates with a susceptible result. 
A second study from Germany by Hufnagel, et al. 
[21], has analyzed enterococcal colonization and 
antimicrobial susceptibility among infants in a neo-
natal intensive care unit. Over a 12-month period, 
they performed a prospective epidemiological study 
in 274 infants admitted to a neonatal intensive care 
unit. Twenty-three percent of the infants were colo-
nized with enterococci. The three most common 
enterococcal species were E. faecium (48% of iso-
lates), E. casseliflavus (25%) and E. faecalis (13%). 
Fifty-seven percent of the enterococci found were 
resistant to three of five antibiotic classes, but no 
vancomycin-resistant isolates were observed. In 63 
cases (23%), enterococci were isolated from either 
body cultures or from the first meconium. Differen-
tiation at the species level showed 30 (48% of all 
enterococcal isolates) E. faecium, 16 (31%) E. cas-
seliflavus, eight (12%) E. faecalis, two (3%) E. du-
rans, and seven (11%) undifferentiated enterococcal 
species. Thirty-six isolates (57% ) of all enterococcal 
isolates were resistant to three of the five antibiotic 
classes tested (aminopenicillins, carbapenems, ami-
noglycosides, sulfonamides/folinic acid antagonists 
and vancomycin) and were therefore classified as 
multidrug-resistant. All of these multidrug-resistant 
isolates were resistant to aminopenicillins and ami-
noglycosides. Of the 36 multidrug-resistant entero-
cocci, 35 isolates were resistant to both sulfonamides 
and carbapenems. In addition to the 36 multidrug-
resistant isolates, five other isolates were resistant to 
aminoglycoside, and all of them displayed low-level 
aminoglycoside resistance. None of the enterococci 
was vancomycin- resistant. Twenty-four (80%) of E. 
faecium, 11 (69%) of E. casseliflavus, and one (13%) 
E. faecalis isolate were multidrug-resistant.
The study of Dahlen et al. in Sweden [22], evalu-
ated the presence of virulence factors and antibi-
otic susceptibility among enterococcal isolates from 
oral mucosal and deep infections. Forty-three en-
terococcal strains from oral mucosal lesions and 
18 from deep infections were isolated from 830 
samples that were sent during 2 years to Oral Mi-
crobiology, University of Gothenburg, for analysis. 
MIC determination was performed using the E-test 
method against the most commonly used antibiot-
ics in dentistry, for example, penicillin V, amoxicillin 
and clindamycin.Vancomycin was included in order 
to detect vancomycin-resistant enterococci (VRE) 
strains.
Sixty strains were identified as Enterococcus faecalis 
and one as Enterococcus faecium. Ampicillin and 
amoxicillin showed the strongest effect on the ente-
rococci but only 57.4 and 31.1%, respectively, of the 
isolates were susceptible, as screened routinely by 
the disc diffusion method. Using the E-test method 
for estimation of MIC values, all of the E. faecalis 
strains were susceptible as well as the E. faecium 
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isolate for amoxicillin. Of the strains from mucosal 
and deep infection samples, 90% showed minimal 
inhibitory concentrations (MIC90) of 256 mg/ml or 
more against clindamycin.all enterococcal strains 
were sensitive to vancomycin.
The study of Solheim, et al. in Norway [23], has 
showed the wide distribution of virulence genes and 
antibiotic resistance profiles of community-derived 
E. faecalis isolated from the feces of Norwegian in-
fants. Tetracycline resistance was the most preva-
lent resistance trait among the baby isolates (17/31). 
Moreover, a few of the isolates (n = 4) showed high 
level erythromycin and gentamicin resistance. 
General epidemiology of 
enterococci resistance in Arab 
countries
According to our best knowledge by recent search 
of PubMed and other international indexing sourc-
es, we have not found a single study from any Arab 
country which has reported on enterococci infection 
or colonization in infants, while there are many stud-
ies reported about the general incidence and anti-
microbial susceptibility of enterococci isolates from 
clinical specimens or nosocomial infections during 
the last decade (2003-2014). Most of these studies 
showed low to high incidence rates of resistance 
among E. faecalis and E. faecium clinical isolates 
including vancomycin- resistance (23-32). However, 
we have finished recently a study on antimicrobial 
resistance and virulence factors among E. faecalis 
and E. faecium colonizing intestines of Jordanian 
infants. This study will be published within the next 
few months.
Recommended treatment of enterococci infections
The optimal treatment of enterococci bacteremia 
or VRE is ampicillin if the isolates is susceptible to 
this drug, whereas the best treatment in case of 
ampicillin resistance is still under investigation. Lin-
ezolid was successfully used in treatment of invasive 
VRE bacteremia, it has good activity against both 
E. faecalis and E. faecium, develop less resistance 
than other agents and can be given orally and or 
intravenously [33-34]. Linezolid, the first oxazoli-
dinone, has a broad spectrum of activity against 
Gram-positive bacteria, including resistant strains 
such as MRSA and VRE. It has been approved by 
the USA Food and Drug Administration in 2002. 
The available literature data suggest that linezolid is 
a safe and effective agent for the treatment of seri-
ous Gram-positive bacterial infections in neonates 
and children [34]. 
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